Bionime Corporation
TWSE:4737.TW
71.6 (TWD) • At close November 1, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) TWD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1,755.567 | 2,210.589 | 1,849.924 | 1,668.586 | 2,172.923 | 2,007.222 | 1,820.267 | 1,740.309 | 1,609.718 | 1,524.669 | 1,560.897 | 1,435.022 | 1,476.543 | 1,211.743 | 937.752 |
| Cost of Revenue
| 1,039.917 | 1,206.463 | 1,066.793 | 919.461 | 1,224.505 | 1,090.223 | 1,024.494 | 969.822 | 908.426 | 930.048 | 933.106 | 808.812 | 765.313 | 613.956 | 483.471 |
| Gross Profit
| 715.65 | 1,004.126 | 783.131 | 749.125 | 948.418 | 916.999 | 795.773 | 770.487 | 701.292 | 594.621 | 627.791 | 626.21 | 711.23 | 597.787 | 454.281 |
| Gross Profit Ratio
| 0.408 | 0.454 | 0.423 | 0.449 | 0.436 | 0.457 | 0.437 | 0.443 | 0.436 | 0.39 | 0.402 | 0.436 | 0.482 | 0.493 | 0.484 |
| Reseach & Development Expenses
| 242.338 | 201.977 | 187.86 | 247.875 | 255.121 | 201.186 | 159.96 | 140.385 | 117.783 | 92.004 | 101.196 | 100.04 | 100.11 | 63.394 | 46.02 |
| General & Administrative Expenses
| 243.806 | 241.634 | 237.771 | 221.041 | 250.311 | 227.113 | 215.296 | 221.935 | 200.908 | 184.79 | 164.856 | 213.699 | 202.747 | 180.181 | 162.639 |
| Selling & Marketing Expenses
| 279.359 | 399.511 | 302.768 | 235.804 | 276.539 | 249.402 | 172.1 | 149.765 | 192.817 | 168.521 | 216.864 | 241.606 | 214.795 | 153.883 | 95.469 |
| SG&A
| 523.165 | 641.145 | 540.539 | 456.845 | 526.85 | 476.515 | 387.396 | 371.7 | 393.725 | 353.311 | 381.72 | 455.305 | 417.542 | 334.064 | 258.108 |
| Other Expenses
| -728.989 | -15.229 | 17.629 | 30.227 | 10.087 | -49.542 | -37.074 | -22.083 | -8.814 | 2.213 | 1.996 | 13.786 | 10.771 | 8.069 | 12.79 |
| Operating Expenses
| 728.989 | 843.122 | 728.399 | 704.72 | 781.971 | 677.701 | 547.356 | 512.085 | 511.508 | 445.315 | 482.916 | 555.345 | 517.652 | 397.458 | 304.128 |
| Operating Income
| -13.339 | 146.718 | 73.074 | 75.947 | 176.534 | 239.298 | 248.417 | 258.402 | 189.784 | 149.306 | 144.875 | 70.865 | 193.578 | 200.329 | 150.153 |
| Operating Income Ratio
| -0.008 | 0.066 | 0.04 | 0.046 | 0.081 | 0.119 | 0.136 | 0.148 | 0.118 | 0.098 | 0.093 | 0.049 | 0.131 | 0.165 | 0.16 |
| Total Other Income Expenses Net
| -18.536 | -60.235 | 1.511 | -44.836 | -41.967 | -77.335 | -59.615 | -44.471 | -66.555 | -63.42 | -20.797 | -5.468 | 21.981 | -39.046 | 6.042 |
| Income Before Tax
| -31.875 | 86.483 | 74.585 | 31.111 | 134.567 | 161.963 | 188.802 | 213.931 | 123.229 | 85.886 | 124.078 | 65.397 | 215.559 | 161.283 | 156.195 |
| Income Before Tax Ratio
| -0.018 | 0.039 | 0.04 | 0.019 | 0.062 | 0.081 | 0.104 | 0.123 | 0.077 | 0.056 | 0.079 | 0.046 | 0.146 | 0.133 | 0.167 |
| Income Tax Expense
| -38.406 | -5.337 | -14.74 | -32.409 | 27.856 | 34.071 | 39.194 | 35.141 | 24.436 | 31.577 | 34.149 | 31.25 | 36.448 | 25.233 | 20.958 |
| Net Income
| 6.209 | 91.025 | 87.413 | 62.434 | 106.258 | 128.032 | 149.608 | 178.79 | 98.793 | 54.309 | 89.929 | 34.147 | 179.111 | 136.05 | 135.237 |
| Net Income Ratio
| 0.004 | 0.041 | 0.047 | 0.037 | 0.049 | 0.064 | 0.082 | 0.103 | 0.061 | 0.036 | 0.058 | 0.024 | 0.121 | 0.112 | 0.144 |
| EPS
| 0.1 | 1.5 | 1.46 | 1.06 | 1.85 | 2.23 | 2.52 | 2.82 | 1.91 | 1.22 | 2.05 | 0.75 | 4.01 | 3.69 | 3.45 |
| EPS Diluted
| 0.1 | 1.48 | 1.44 | 1.03 | 1.81 | 2.2 | 2.49 | 2.8 | 1.9 | 1.22 | 2.04 | 0.74 | 3.99 | 3.66 | 3.37 |
| EBITDA
| 143.267 | 299.95 | 227.731 | 239.429 | 341.019 | 341.091 | 357.14 | 394.333 | 334.317 | 299.063 | 252.214 | 179.687 | 293.879 | 205.864 | 185.601 |
| EBITDA Ratio
| 0.082 | 0.136 | 0.123 | 0.143 | 0.157 | 0.17 | 0.196 | 0.227 | 0.208 | 0.196 | 0.162 | 0.125 | 0.199 | 0.17 | 0.198 |